Product correctly added to cart.

discount label
Otenzepad
View 3D

Targetmol logo

Otenzepad

CAS: 102394-31-0

Ref. TM-T16411

1mg
46.00 €
5mg
83.00 €
10mg
130.00 €
25mg
266.00 €
50mg
427.00 €
100mg
631.00 €
1mL*10mM (DMSO)
91.00 €
Estimated delivery in United States, on Thursday 30 Jan 2025

Product Information

Name:
Otenzepad
Synonyms:
  • AF-DX 116
  • 11-((2-((Diethylamino)methyl)-1-piperidinyl)acetyl)-5,11-dihydro-(6H)-pyrido[2.3-b][1.4]benzodiazepin-6-one
  • 11-[2-[2-(Diethylaminomethyl)piperidin-1-yl]acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
  • 11-[2-[2-[(Diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one
  • 6H-Pyrido(2,3-B)(1,4)Benzodiazepin-6-One,5,11-Dihydro-11-((2-((Diethylamino)M
  • 6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-
  • 6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 11-[[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-
  • Af-Dx 116
  • Ethyl)-7-Piperidinyl)Acetyl)-
Description:

Otenzepad (AF-DX 116) is a selective antagonist of M2 mAChR with IC50s of 386 nM and 640 nM for rat heart and rabbit peripheral lung.

Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Targetmol
Long term storage:
Notes:

Chemical properties

Molecular weight:
421.54
Formula:
C24H31N5O2
Purity:
99.81%
Color/Form:
Solid
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:

Hazard Info

UN Number:
EQ:
Class:
H Statements:
P Statements:
Forbidden to fly:
Hazard Info:
Packing Group:
LQ:

Technical inquiry about: TM-T16411 Otenzepad

Please use instead the cart to request a quotation or an order

If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.

* Mandatory fields.
Welcome to CymitQuimica!We use cookies to enhance your visit. We do not include advertising.

Please see our Cookies Policy for more details or adjust your preferences in "Settings".